# A Phase 3 Clinical Study of QLM3004 in Delaying Myopia in Children

> **NCT06151587** · PHASE3 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 735 (estimated)

## Conditions studied

- Myopia

## Interventions

- **DRUG:** QLM3004 Concentration 1
- **DRUG:** QLM3004 Concentration 2
- **DRUG:** QLM3004 Concentration 3
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06151587
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-20
- **Primary completion:** 2026-06
- **Final completion:** 2027-06
- **Target enrollment:** 735 (ESTIMATED)
- **Last updated:** 2023-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06151587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06151587, "A Phase 3 Clinical Study of QLM3004 in Delaying Myopia in Children". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06151587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*